INmune Bio, Inc. (INMB)
INMB Stock Price Chart
Explore INmune Bio, Inc. interactive price chart. Choose custom timeframes to analyze INMB price movements and trends.
INMB Company Profile
Discover essential business fundamentals and corporate details for INmune Bio, Inc. (INMB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Feb 2019
Employees
13.00
Website
https://www.inmunebio.comCEO
Raymond Joseph Tesi
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INMB Financial Timeline
Browse a chronological timeline of INmune Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Mar 2026
Upcoming earnings on 30 Oct 2025
EPS estimate is -$0.31.
Earnings released on 7 Aug 2025
EPS came in at -$0.34 surpassing the estimated -$0.37 by +8.11%.
Earnings released on 8 May 2025
EPS came in at -$0.43 matching the estimated -$0.43, while revenue for the quarter reached $50.00K .
Earnings released on 27 Mar 2025
EPS came in at -$0.40 surpassing the estimated -$0.54 by +25.93%.
Earnings released on 31 Oct 2024
EPS came in at -$0.60 falling short of the estimated -$0.49 by -22.45%.
Earnings released on 1 Aug 2024
EPS came in at -$0.50 surpassing the estimated -$0.63 by +20.63%.
Earnings released on 9 May 2024
EPS came in at -$0.61 falling short of the estimated -$0.53 by -15.09%, while revenue for the quarter reached $14.00K , missing expectations by -53.33%.
Earnings released on 28 Mar 2024
EPS came in at -$0.47 falling short of the estimated -$0.44 by -6.82%, while revenue for the quarter reached $28.00K , missing expectations by -30.00%.
Earnings released on 1 Nov 2023
EPS came in at -$0.48 falling short of the estimated -$0.39 by -23.08%, while revenue for the quarter reached $43.00K , beating expectations by +7.50%.
Earnings released on 7 Aug 2023
EPS came in at -$0.36 surpassing the estimated -$0.40 by +10.00%, while revenue for the quarter reached $46.00K , beating expectations by +21.05%.
Earnings released on 3 May 2023
EPS came in at -$0.36 falling short of the estimated -$0.02 by -1.70K%, while revenue for the quarter reached $38.00K .
Earnings released on 2 Mar 2023
EPS came in at -$0.32 surpassing the estimated -$0.48 by +33.33%, while revenue for the quarter reached $97.00K .
Earnings released on 2 Nov 2022
EPS came in at -$0.43 surpassing the estimated -$0.59 by +27.12%, while revenue for the quarter reached $98.00K .
Earnings released on 3 Aug 2022
EPS came in at -$0.38 surpassing the estimated -$0.50 by +24.00%, while revenue for the quarter reached $16.00K .
Earnings released on 5 May 2022
EPS came in at -$0.39 surpassing the estimated -$0.60 by +35.00%, while revenue for the quarter reached $163.00K , missing expectations by -28.09%.
Earnings released on 3 Mar 2022
EPS came in at -$0.55 surpassing the estimated -$0.56 by +1.79%, while revenue for the quarter reached $163.00K .
Earnings released on 3 Nov 2021
EPS came in at -$0.55 falling short of the estimated -$0.43 by -27.91%, while revenue for the quarter reached $14.00K , missing expectations by -98.56%.
Earnings released on 4 Aug 2021
EPS came in at -$0.44 falling short of the estimated -$0.33 by -33.33%.
Earnings released on 5 May 2021
EPS came in at -$0.32 falling short of the estimated -$0.28 by -14.29%, while revenue for the quarter reached $4.00K , beating expectations by +22.74%.
Earnings released on 4 Mar 2021
EPS came in at -$0.24 surpassing the estimated -$0.33 by +27.27%, while revenue for the quarter reached $10.92K .
Earnings released on 5 Nov 2020
EPS came in at -$0.36 falling short of the estimated -$0.17 by -111.76%.
INMB Stock Performance
Access detailed INMB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.